• Researchers in lab working on OncoVAX Cancer Vaccine while wearing protective body suit

Vaccinogen believes the battle to end cancer recurrence requires a customized attack. Every tumor is unique and needs to be treated as such.

Vaccinogen is an industry leading patient-specific, tumor-based immunotherapy company with phase III data demonstrating that its lead product, OncoVAX®, reduces stage II colon cancer recurrence from one in three patients to one in ten.